Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
| ▸ | ENO1 | P06733 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4891818 | 0.99 | F2RL3 (0.33) | F2RL3PTPN2PTPN1L3MBTL1HDAC6 | |
| SCHEMBL4898644 | 0.89 | PTPN1 (0.31) | PTPN2PTPN1 | |
| SCHEMBL14257198 | 0.89 | PTPN1 (0.36) | PTPN2PTPN1L3MBTL1MAPK10MAPK8 | |
| SCHEMBL14257179 | 0.89 | AR (0.34) | PTPN2PTPN1L3MBTL1HDAC6ALDH1A1 | |
| SCHEMBL4901576 | 0.84 | F2RL3 (0.43) | F2RL3PTPN2PTPN1L3MBTL1MAPK10 | |
| SCHEMBL14257181 | 0.83 | AR (0.34) | L3MBTL1HDAC6ALDH1A1ENO1HDAC1 | |
| SCHEMBL4956718 | 0.83 | PTPN1 (0.31) | PTPN2PTPN1 | |
| SCHEMBL4898662 | 0.82 | NOTUM (0.33) | PTPN2L3MBTL1HDAC6ALDH1A1MAPK10 | |
| SCHEMBL4903704 | 0.82 | MAPK10 (0.42) | PTPN2PTPN1L3MBTL1ALDH1A1MAPK10 | |
| SCHEMBL4901328 | 0.82 | MAPK10 (0.42) | PTPN2PTPN1L3MBTL1ALDH1A1MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070867-A1 | 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases | METABASIS THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| WO-2006078698-A1 | 2-IMIDAZOLONE AND 2-IMIDAZOLIDINONE HETEROCYCLIC INHIBITORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070867-A1 | 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases | PPM1B, PPM1D, PTPRS | F2RL3 4655/4885PTPN2 27/4885PTPN1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.